September 22, 2024Open Access

Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells

View Full Paper

Ask AI

Bookmark

Authors

SMScott McCombUniversity of Ottawa BDBianca DupontUniversity of Ottawa ASAlex ShepherdUniversity of Ottawa

Discussion

Member takes

Implication

Preclinical study demonstrates that dual-clonal anti-VHH antibodies regulate and expand nanobody CAR-T cells, highlighting a versatile platform for manufacturing cellular therapies.

Key Points

Potent inhibition of chimeric antigen receptor cytolytic killing is achieved using dual-clonal anti-VHH antibodies targeting conserved framework regions.
Over 98% of tested nanobodies react with the dual-clonal reagent, which subsequently drives a 730-fold mean expansion without inducing functional exhaustion.
Assessment using immobilized anti-VHH antibodies demonstrates robust expansion and labeling of therapeutic cells; preclinical cell model, further in vivo testing needed.

Cite This Study

McComb et al. (2024) studied this question.

synapsesocial.com/papers/68e57aefb6db64358751abb1 https://doi.org/10.1101/2024.09.18.613561

View Full Paper

Ask AI

Bookmark

September 22, 2024Open Access

Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells

View Full Paper

Ask AI

Bookmark

Authors

SMScott McCombUniversity of Ottawa BDBianca DupontUniversity of Ottawa ASAlex ShepherdUniversity of Ottawa

Discussion

Member takes

Implication

Preclinical study demonstrates that dual-clonal anti-VHH antibodies regulate and expand nanobody CAR-T cells, highlighting a versatile platform for manufacturing cellular therapies.

Key Points

Potent inhibition of chimeric antigen receptor cytolytic killing is achieved using dual-clonal anti-VHH antibodies targeting conserved framework regions.
Over 98% of tested nanobodies react with the dual-clonal reagent, which subsequently drives a 730-fold mean expansion without inducing functional exhaustion.
Assessment using immobilized anti-VHH antibodies demonstrates robust expansion and labeling of therapeutic cells; preclinical cell model, further in vivo testing needed.

Cite This Study

McComb et al. (2024) studied this question.

synapsesocial.com/papers/68e57aefb6db64358751abb1 https://doi.org/10.1101/2024.09.18.613561

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark